NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
CITANEST FORTE (epinephrine bitartrate; prilocaine hydrochloride) by AstraZeneca is mechanism of action prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1965.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CITANEST FORTE is a fixed-dose combination injectable containing prilocaine hydrochloride (local anesthetic) and epinephrine bitartrate (vasconstrictor), approved in 1965 for infiltration and regional anesthesia. Prilocaine works by stabilizing neuronal membranes to block impulse conduction, while epinephrine prolongs duration and reduces systemic absorption. This combination is used primarily in dental, surgical, and procedural settings where rapid, reversible local anesthesia is required.
LOE Approaching
As a decades-old local anesthetic approaching loss of exclusivity, CITANEST FORTE operates in a mature, commoditized market with moderate competitive pressure (30/100), suggesting a small, efficiency-focused commercial team managing brand defense rather than growth.
Mechanism of Action
Mechanism of Action Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CITANEST FORTE offers limited career growth opportunities given its mature LOE stage and zero linked job openings; roles focus on defending market share, managing generic competition, and optimizing costs rather than launching or scaling. This is typically a stable but narrower career path suited to professionals seeking operational expertise or portfolio management in a legacy product context.
Brand Manager
Worked on CITANEST FORTE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.